Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Stuart A. Arbuckle sold 2,156 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $169.42, for a total transaction of $365,269.52. Following the completion of the transaction, the executive vice president now directly owns 44,108 shares of the company’s stock, valued at approximately $7,472,777.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down $11.10 during trading on Monday, hitting $155.14. 2,869,864 shares of the company were exchanged, compared to its average volume of 1,780,000. The company has a current ratio of 4.79, a quick ratio of 4.58 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $39,240.00, a price-to-earnings ratio of 79.56, a P/E/G ratio of 2.51 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $84.39 and a fifty-two week high of $174.96.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. The business had revenue of $651.63 million during the quarter, compared to analyst estimates of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. Vertex Pharmaceuticals’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.35 earnings per share. equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 1.58 earnings per share for the current fiscal year.
Several research analysts recently issued reports on VRTX shares. Cowen reissued a “buy” rating and issued a $200.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, December 11th. Deutsche Bank started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $175.00 price objective for the company. Bank of America raised shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $180.00 price objective for the company in a report on Friday, January 5th. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and twenty-five have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $180.07.
Several institutional investors have recently modified their holdings of VRTX. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 19.0% in the third quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after purchasing an additional 962,644 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Vertex Pharmaceuticals by 8,061.1% in the third quarter. Point72 Asset Management L.P. now owns 909,230 shares of the pharmaceutical company’s stock valued at $138,239,000 after purchasing an additional 898,089 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Vertex Pharmaceuticals by 9,422.3% in the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after purchasing an additional 883,998 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Vertex Pharmaceuticals by 1,191.3% in the second quarter. Janus Henderson Group PLC now owns 448,975 shares of the pharmaceutical company’s stock valued at $57,860,000 after purchasing an additional 414,206 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its holdings in shares of Vertex Pharmaceuticals by 88.1% in the second quarter. Lord Abbett & CO. LLC now owns 459,059 shares of the pharmaceutical company’s stock valued at $59,159,000 after purchasing an additional 215,062 shares in the last quarter. 92.81% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/05/insider-selling-vertex-pharmaceuticals-incorporated-vrtx-evp-sells-2156-shares-of-stock.html.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.